Literature DB >> 23995321

Does cirrhotic cardiomyopathy exist? 50 years of uncertainty.

Pierpaolo Pellicori1, Concetta Torromeo, Angela Calicchia, Alessandra Ruffa, Martina Di Iorio, John G F Cleland, Manuela Merli.   

Abstract

Subtle abnormalities of cardiac structure or function are often identified in patients with liver cirrhosis and have been termed cirrhotic cardiomyopathy. However, in the absence of a precise definition, its diagnosis remains a challenge. Cardiac dysfunction in patients with cirrhosis can often be attributed to concomitant diseases such as hypertension, ischaemic heart disease or excess alcohol consumption in many patients. Further research is required to identify the existence, origin and importance of abnormal cardiac function due specifically to liver disease. Cardiac dysfunction may be masked by treatments given to cirrhotic patients, such as mineral-corticoid receptor antagonists, or by co-existing conditions, such as anaemia. New imaging tests or plasma biomarkers might be able to detect abnormal cardiac function at an early stage of its development.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23995321     DOI: 10.1007/s00392-013-0610-1

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  64 in total

1.  Serum galectin-3 levels in patients with nonalcoholic fatty liver disease.

Authors:  Yusuf Yilmaz; Fatih Eren; Ramazan Kurt; Oya Yonal; Zulfikar Polat; Ebubekir Senates; Mohammad Bacha; Nese Imeryuz
Journal:  Clin Biochem       Date:  2011-05-24       Impact factor: 3.281

2.  Eplerenone in patients with systolic heart failure and mild symptoms.

Authors:  Faiez Zannad; John J V McMurray; Henry Krum; Dirk J van Veldhuisen; Karl Swedberg; Harry Shi; John Vincent; Stuart J Pocock; Bertram Pitt
Journal:  N Engl J Med       Date:  2010-11-14       Impact factor: 91.245

3.  Impaired left ventricular function in alcoholic cirrhosis with ascites. Ineffectiveness of ouabain.

Authors:  C J Limas; N H Guiha; O Lekagul; J N Cohn
Journal:  Circulation       Date:  1974-04       Impact factor: 29.690

4.  QT interval in patients with non-cirrhotic portal hypertension and in cirrhotic patients treated with transjugular intrahepatic porto-systemic shunt.

Authors:  Franco Trevisani; Manuela Merli; Francesco Savelli; Valentina Valeriano; Andrea Zambruni; Oliviero Riggio; Paolo Caraceni; Marco Domenicali; Mauro Bernardi
Journal:  J Hepatol       Date:  2003-04       Impact factor: 25.083

5.  Resting myocardial dysfunction in cirrhosis quantified by tissue Doppler imaging.

Authors:  Konstantin Kazankov; Peter Holland-Fischer; Niels H Andersen; Peter Torp; Erik Sloth; Niels K Aagaard; Hendrik Vilstrup
Journal:  Liver Int       Date:  2011-02-15       Impact factor: 5.828

6.  The fibrosis marker galectin-3 and outcome in the general population.

Authors:  R A de Boer; D J van Veldhuisen; R T Gansevoort; A C Muller Kobold; W H van Gilst; H L Hillege; S J L Bakker; P van der Harst
Journal:  J Intern Med       Date:  2011-11-18       Impact factor: 8.989

7.  Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma.

Authors:  G P Rossi; A Sacchetto; E Pavan; P Palatini; G R Graniero; C Canali; A C Pessina
Journal:  Circulation       Date:  1997-03-18       Impact factor: 29.690

8.  Diastolic myocardial dysfunction does not affect survival in patients with cirrhosis.

Authors:  Alexandra Alexopoulou; George Papatheodoridis; Sophia Pouriki; Christina Chrysohoou; Leonidas Raftopoulos; Christodoulos Stefanadis; Dimitrios Pectasides
Journal:  Transpl Int       Date:  2012-08-21       Impact factor: 3.782

9.  Longitudinal ventricular function: normal values of atrioventricular annular and myocardial velocities measured with quantitative two-dimensional color Doppler tissue imaging.

Authors:  Nikolay P Nikitin; Klaus K A Witte; Simon D R Thackray; Ramesh de Silva; Andrew L Clark; John G F Cleland
Journal:  J Am Soc Echocardiogr       Date:  2003-09       Impact factor: 5.251

10.  Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction.

Authors:  Rudolf A de Boer; Dirk J A Lok; Tiny Jaarsma; Peter van der Meer; Adriaan A Voors; Hans L Hillege; Dirk J van Veldhuisen
Journal:  Ann Med       Date:  2010-12-28       Impact factor: 4.709

View more
  4 in total

Review 1.  Cirrhotic Multiorgan Syndrome.

Authors:  Søren Møller; Flemming Bendtsen
Journal:  Dig Dis Sci       Date:  2015-06-26       Impact factor: 3.199

2.  Impact of Cirrhotic Cardiomyopathy Diagnosed According to Different Criteria on Patients with Cirrhosis Awaiting Liver Transplantation: A Retrospective Cohort Study.

Authors:  Achintya D Singh; Andrew Ford; Ruishen Lyu; Habib Layoun; Serge C Harb; Maan Fares; William D Carey
Journal:  Dig Dis Sci       Date:  2022-02-12       Impact factor: 3.487

Review 3.  Cirrhotic cardiomyopathy.

Authors:  Luis Ruiz-del-Árbol; Regina Serradilla
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

Review 4.  Recent advances in the diagnosis and management of cirrhosis-associated cardiomyopathy in liver transplant candidates: advanced echo imaging, cardiac biomarkers, and advanced heart failure therapies.

Authors:  Maryjane Farr; Paul Christian Schulze
Journal:  Clin Med Insights Cardiol       Date:  2015-01-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.